Nineteen novel drugs have been selected for inclusion in the first iteration of China's Commercial Health Insurance Innovative Drug Catalogue, portending potential access benefits as the program gains ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.
Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new Chinese biotech OTR Therapeutics to work on drugs for metabolic diseases.
Health insurance companies are expected to hold to their promises in 2026 to “streamline, simplify and reduce” prior ...
Millions rely on Medicare Part D, but many prescription drugs won't be covered in 2026. See which meds are excluded, why, and ...
In an October press release, the Office of the Attorney General laid out its complaint, accusing drugmakers and PBMs of ...
MedPage Today on MSN
New CMS Demo Aims to Increase Access to GLP-1s Under Medicaid and Part D
The Trump administration announced a new demonstration program aimed at easing access to GLP-1 receptor agonists for ...
A daily preventive pill can be invaluable for people at risk for HIV. But some doctors don't know much about prescribing them ...
Medicare Part D covers prescription drugs for millions of Americans. By 2025, out-of-pocket expenses will be capped at $2,000 ...
In an announcement on November 25, 2025, the Centers for Medicare & Medicaid Services (CMS) revealed the new Maximum Fair ...
Here are five ways AARP has fought to make lower drug prices a top priority. The 2003 law that created Medicare Part D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback